

=====

Sequence Listing was accepted.

See attached Validation Report.

If you need help call the Patent Electronic Business Center at (866)
217-9197 (toll free).

Reviewer: Durreshwar Anjum

Timestamp: Fri Nov 02 12:50:16 EDT 2007

=====

Application No: 10594992 Version No: 1.0

Input Set:

Output Set:

Started: 2007-10-17 10:08:22.446
Finished: 2007-10-17 10:08:23.259
Elapsed: 0 hr(s) 0 min(s) 0 sec(s) 813 ms
Total Warnings: 8
Total Errors: 1
No. of SeqIDs Defined: 8
Actual SeqID Count: 8

Error code	Error Description
W 213	Artificial or Unknown found in <213> in SEQ ID (1)
W 213	Artificial or Unknown found in <213> in SEQ ID (2)
E 257	Invalid sequence data feature in <221> in SEQ ID (2)
W 213	Artificial or Unknown found in <213> in SEQ ID (3)
W 213	Artificial or Unknown found in <213> in SEQ ID (4)
W 213	Artificial or Unknown found in <213> in SEQ ID (5)
W 213	Artificial or Unknown found in <213> in SEQ ID (6)
W 213	Artificial or Unknown found in <213> in SEQ ID (7)
W 213	Artificial or Unknown found in <213> in SEQ ID (8)

SEQUENCE LISTING

<110> BIOMIRA, INC.
LONGENECKER, MICHAEL B.

<120> MUCINOUS GLYCOPROTEIN (MUC-1) VACCINE

<130> 042881-0227

<140> 10594992

<141> 2007-10-17

<150> PCT/IB05/002479

<151> 2005-04-01

<150> 60/576,804

<151> 2004-06-04

<150> 60/558,139

<151> 2004-04-01

<160> 8

<170> PatentIn Ver. 3.3

<210> 1

<211> 25

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<400> 1

Ser Thr Ala Pro Pro Ala His Gly Val Thr Ser Ala Pro Asp Thr Arg
1 5 10 15

Pro Ala Pro Gly Ser Thr Ala Pro Pro
20 25

<210> 2

<211> 27

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<220>

<221> MOD_RES

<222> (26)

<223> Lys (palmitoyl)

<400> 2

Ser Thr Ala Pro Pro Ala His Gly Val Thr Ser Ala Pro Asp Thr Arg
1 5 10 15

Pro Ala Pro Gly Ser Thr Ala Pro Pro Lys Gly
20 25

<210> 3

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<400> 3

Ser Thr Ala Pro Pro Ala His Gly Val Thr Ser Ala Pro Asp Thr Arg
1 5 10 15

Pro Ala Pro Gly
20

<210> 4

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<400> 4

Gly Ser Thr Ala Pro Pro Ala His Gly Val Thr Ser Ala Pro Asp Thr
1 5 10 15

Arg Pro Ala Pro
20

<210> 5

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<400> 5

Gly Val Thr Ser Ala Pro Asp Thr Arg Pro Ala Pro Gly Ser Thr Ala
1 5 10 15

Pro Pro Ala His
20

<210> 6
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<400> 6
Pro Asp Thr Arg Pro Ala Pro Gly Ser Thr Ala Pro Pro Ala His Gly
1 5 10 15

Val Thr Ser Ala
20

<210> 7
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<400> 7
His Gly Val Thr Ser Ala Pro Asp Thr Arg Pro Ala Pro Gly Ser Thr
1 5 10 15

Ala Pro Pro Ala
20

<210> 8
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<400> 8
Val Thr Ser Ala Pro Asp Thr Arg Pro Ala Pro Gly Ser Thr Ala Pro
1 5 10 15

Pro Ala His Gly
20